VeriMomБезопасен ли oligopeptide-126 sh-oligopeptide-1 при беременности?
No harmonised CLP reproductive classifications (ECHA Annex VI) or CIR/SCCS safety opinions identify reproductive or developmental hazard for cosmetic use of EGF/oligopeptide ingredients. Peer‑reviewed literature documents biological activity of EGF in tissues but does not provide evidence of maternal reproductive toxicity following topical cosmetic use; dermal bioavailability of large peptides is expected to be negligible (sources: ECHA Annex VI (no harmonised H360/H361), CIR/SCCS absence of adverse findings in cosmetic peptide assessments, PubMed literature on EGF topical use).
Related ingredients
Frequently asked questions
- Безопасен ли oligopeptide-126 sh-oligopeptide-1 при беременности?
- No harmonised CLP reproductive classifications (ECHA Annex VI) or CIR/SCCS safety opinions identify reproductive or developmental hazard for cosmetic use of EGF/oligopeptide ingredients. Peer‑reviewed literature documents biological activity of EGF in tissues but does not provide evidence of maternal reproductive toxicity following topical cosmetic use; dermal bioavailability of large peptides is expected to be negligible (sources: ECHA Annex VI (no harmonised H360/H361), CIR/SCCS absence of adverse findings in cosmetic peptide assessments, PubMed literature on EGF topical use).
- Безопасен ли oligopeptide-126 sh-oligopeptide-1 при грудном вскармливании?
- No evidence from regulatory sources or peer‑reviewed studies that topical oligopeptide‑1 causes reproductive or lactation toxicity or transfers into breastmilk after cosmetic topical use; expected negligible systemic absorption of large peptides reduces lactational exposure (sources: PubMed, CosIng, PubChem entries for peptide cosmetic ingredients; no harmonised CLP classifications).
- Безопасен ли oligopeptide-126 sh-oligopeptide-1 для кожи малыша?
- Hazard and mechanism: no specific developmental or reproductive hazard shown for topical oligopeptide‑1 (h=0,m=0). Exposure: increase by +1 for infants because skin barrier immaturity can increase dermal uptake compared with adults; although large peptides have low dermal penetration, measurable absorption cannot be ruled out for compromised/immature skin, so e=1 for 0–3 yr (sources: general dermal pharmacokinetic principles in PubMed, CosIng listing of peptide cosmetic use; no specific infant studies found).
- Как VeriMom оценивает oligopeptide-126 sh-oligopeptide-1?
- VeriMom оценивает oligopeptide-126 sh-oligopeptide-1 в 100/100 (без известных рисков) на основе EU CosIng, классификаций ECHA и исследований PubMed.
- Какие безопасные альтернативы oligopeptide-126 sh-oligopeptide-1 при беременности?
- См. наш список безопасных альтернатив oligopeptide-126 sh-oligopeptide-1 с аналогичной функцией и классификацией без известных рисков.
Проверь любой состав за 2 секунды
Скачай VeriMom бесплатно — отсканируй любой продукт и мгновенно получи оценку безопасности при беременности.
Медицинская оговорка
Данная информация предоставлена исключительно в образовательных целях и не является медицинской рекомендацией. Оценки безопасности основаны на общедоступных данных и могут не отражать все риски. Всегда консультируйтесь с вашим врачом перед использованием любых средств во время беременности или грудного вскармливания.